Multifocal angiostatic therapy (MAT) is a strategy that seeks to impede cancer-induced angiogenesis by addressing multiple targets that regulate the angiogenic capacity of a cancer and/or the angiogenic responsiveness of endothelial cells, using measures that are preferentially, but not exclusively, nutraceutical. A prototype of such a regimen has been proposed previously, composed of green tea polyphenols, fish oil, selenium, and high-dose glycine, complementing a low-fat vegan diet, exercise training, and the copper-sequestering drug tetrathiomolybdate (TM). A review of more recent evidence suggests additional agents that could appropriately be included in this regimen and clarifies to some extent the mechanisms of action of its constituents. Diindolylmethane, a widely available crucifera-derived nutraceutical, has inhibited cancer growth in several mouse xenograft models; this effect may be largely attributable to an angiostatic action, as concentrations as low as 5 to 10 µM inhibit proliferation, migration, and tube-forming capacity of human endothelial cells in vitro, and a parenteral dose of 5 mg/kg markedly impairs matrigel angiogenesis in mice. Silymarin/silbinin, which has slowed the growth of human xenografts in a number of studies, suppresses the proliferation, migration, and tube-forming capacity of endothelial cells and inhibits vascular endothelial growth factor (VEGF) secretion by a range of human cancer cell lines, in concentrations that should be clinically feasible. The angiostatic activity of orally administered green tea now appears likely to reflect inhibition of the kinase activity of VEGFR-2. Glycine's angiostatic activity may be attributable to a hyperpolarizing effect on endothelial cells that decreases the activity of NADPH oxidase, now known to promote tyrosine kinase signaling in endothelial cells. The ability of TM to suppress cancer cell production of a range of angiogenic factors results at least in part from a downregulation of NF-κB activation. Dual-purpose molecular targets, whose inhibition could be expected to decrease the aggressiveness and chemoresistance of cancer cells while simultaneously impeding angiogenesis, include NF-κB, cox-2, c-Src, Stat3, and hsp90; drugs that can address these targets are now in development, and salicylates are notable for the fact that they can simultaneously inhibit NF-κB and cox-2. The potential complementary of the components of MAT should be assessed in nude mouse xenograft models.
Nutraceuticals Versus Angiogenesis
Multifocal angiostatic therapy (MAT) has been defined as a strategy for suppressing tumor-evoked angiogenesis by addressing multiple complementary targets in endothelial cells and in cancer cells. An explicit example of such a protocol, making use of welltolerated nutraceutical agents and lifestyle strategies in conjunction with the copper-sequestering drug tetrathiomolybdate (TM), has been proposed. 1 The measures envisioned in this proposal include a verylow-fat vegan diet complemented by aerobic exercise training (intended to downregulate plasma levels of insulin and free IGF-I) and supplementary intakes of green tea polyphenols, omega-3-rich fish oil, selenium, and high-dose glycine. High-dose zinc supplementation was suggested as a possible alternative to TM as a strategy for achieving angiostatic copper depletion-albeit TM therapy would seem likely to have greater efficacy in this regard. Some of these measures can be expected to act on cancer cells to diminish their capacity to secrete angiogenic factors, whereas others directly target endothelial cells, suppressing their responsiveness to these factors. Arguably, the latter category is more intriguing, as these measures would be expected to have general and durable efficacy in the management of all solid tumors, whereas agents targeting cancer could become less efficacious over time as resistant clones were selected for.
Since the original discussion of MAT was submitted 4 years ago, a number of studies have appeared that suggest the likely utility of additional measures as components of MAT or that provide insight into the mechanism of action of measures previously proposed. Furthermore, more evidence is now available regarding certain dual targets in cancers and endothelial cells, molecular targets whose inhibition would be expected to slow the growth or spread of cancer cells while simultaneously acting directly on endothelial cells to impede the process of angiogenesis. These issues will be addressed below.
Diindolylmethane
Diindolylmethane (DIM) is a metabolite of indole-3carbinol, a phytochemical produced in cruciferous vegetables when these vegetables are crushed, enabling the enzyme myrosinase to gain access to and cleave the glucosinolate compound glucobrassicin. 2 When indole-3-carbinol is ingested orally, gastric acid-catalyzed condensation of 2 molecules of indole-3-carbinol generates 1 molecule of DIM. There has been considerable speculation that DIM may have chemopreventive utility, as it acts on the liver to induce mixed-function oxidase activity (CYP1A1) that converts estradiol to its innocuous 2-hydroxy derivative, concurrently diminishing the 16-hydroxylation of this hormone; the latter metabolite has greater estrogenic activity-thus acting as a promoter for estrogendependent tumors-and also has direct carcinogenic activity. 3, 4 More recently, however, studies in mouse xenograft models as well as in cancer cell cultures have suggested that DIM may have potential in cancer therapy. In particular, DIM administration has been shown to slow the growth of DMBA-induced mammary cancers in rats, the TRAMP-C2 murine prostate cancer in mice, and xenografts of the human MCF-7 mammary cancer in nude mice. [5] [6] [7] Tumor growth retardation of at least 50% has been observed after administration of rather moderate doses of DIM (5-10 mg/kg intraperitoneally or subcutaneously [sc] ). These reports are especially intriguing in light of the fact that supplementary DIM is now sold freely in the United States as a putative chemopreventive agent, with suggested daily intakes as high as 400 mg, well within the range of intake that slows cancer growth in rodents (albeit DIM was administered parenterally in these studies).
The most recent of these studies is of particular interest, inasmuch as it provides evidence that an angiostatic effect, directly targeting endothelial cells, may be largely responsible for the observed retardation of tumor growth. 7 Thus, in concentrations as low as 5 µM (about 10-fold lower than concentrations that boost cancer cell apoptosis in vitro [8] [9] [10] [11] ), DIM slows the proliferation of human umbilical vein endothelial cells (HUVECs), an effect associated with reduced expression of the cyclin-dependent kinases CDK2 and CDK6, increased expression of the cdk inhibitor p27, and accumulation of endothelial cells in G1 phase. At concentrations of 10 µM or higher, DIM also inhibited migration of endothelial cells in the Boyden chamber assay and suppressed tube formation in culture. In mice, DIM (5 mg/kg sc daily) suppressed by up to 74% the angiogenesis elicited by Matrigel plugs infused with acidic fibroblast growth factor. Finally, the same DIM regimen was shown to inhibit quite markedly the growth of MCF-7 cells in nude mice; when the study was terminated 34 days postimplantation, the tumor volumes in the DIM-treated mice averaged 64% less than in control mice. Unfortunately, the work done to date does not clarify the proximal molecular target of DIM's antiangiogenic activity; it is hoped that studies are in process to address this issue and to provide further confirmation of DIM angiostatic activity.
The interpretation of studies in which DIM has slowed tumor growth in rodents is complicated by the fact that DIM may have antiestrogenic activity stemming from activation of aryl hydrocarbon receptors. 5 Nonetheless, this would not likely account for the impact of DIM on growth of the TRAMP-C2 prostate cancer. It would be worthwhile to examine the impact of DIM on a range of cancer xenografts not known to be estrogen responsive; if DIM's cancer-retardant activity does indeed reflect an angiostatic effect targeting endothelial cells, one would expect it to show activity against most if not all transplanted tumors.
The fact that DIM is currently sold as a nutraceutical, with recommended doses as high as 400 mg daily, suggests that it is reasonably well tolerated in doses that might be sufficient for anticancer activity, presuming that results in rodents can be extrapolated to humans. However, DIM is poorly water soluble, and rodent studies documenting its efficacy have administered it parenterally; thus, the extent to which DIM is absorbed after oral administration will have implications for the dose ranges that might be useful clinically.
Silymarin/Silibinin
Another agent that has emerged recently as a likely candidate for inclusion in MAT protocols is the flavonolignan silibinin, the chief constituent of the well-known nutraceutical silymarin. The latter is an extract of milk thistle (Silybum marianum [L.] Gaertn., Asteraceae) that has been used for decades to treat a range of hepatic disorders; it does indeed appear to have some clinical utility in this regard. 12 Silibinin's clinical efficacy may be attributable, in part, to the fact that comparatively substantial plasma concentrations can be achieved and maintained after oral administration. Thus, in rodent studies, plasma concentrations of 20 µM or even higher have been measured. 13, 14 This contrasts notably with the pharmacokinetics of the green tea polyphenol epigallocatechingallate (EGCG); in phase I/phase II clinical evaluations of this agent, it usually has not been possible to achieve plasma levels of unconjugated EGCG in excess of 1 µM. 15, 16 Silibinin differs from many other flavonoids in that the hydroxyl groups in the B ring have been blocked by condensation with the lignan coniferyl alcohol; perhaps this contributes to its favorable pharmacokinetics.
Oral silibinin, administered in the diet at concentrations ranging from 0.05% to 0.5%, has been shown to slow the growth of human xenografts in nude mice (DU145 prostate cancer and the non-small-cell lung carcinoma A549) and of established skin papillomas in SENCAR mice. [17] [18] [19] Antiproliferative, proapoptotic, and chemosensitizing effects of silibinin on a range of cancer cells in vitro have also been reported. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Downregulation of NF-κB may be at least partially responsible for direct effects of silibinin on cancer cell behavior; this agent appears to inhibit IκB kinase-α activity, which often (though not invariably) contributes to the activation of NF-κB. [30] [31] [32] One of NF-κB's transcriptional targets is vascular endothelial growth factor (VEGF); it is thus not surprising that, in vitro, silibinin has been found to inhibit VEGF secretion by human breast, prostate, and colon cancer cell lines, in concentrations that may be clinically achievable. [33] [34] [35] In vivo, silibinin has been shown to suppress neovascularization in the chorioallantoic membrane assay (using implanted human colon cancer cells as a stimulus), as well as in DU145 xenografts 36, 37 ; in the latter study, tumor vasculature was diminished by 21% to 38%, as assessed by staining for the CD31 endothelial cell marker.
Could silibinin exert angiostatic effects directly on endothelial cells? Several recent studies offer support for this proposition. An early effort to assess silibinin's direct impact on endothelial cells was marred by the fact that the lowest concentration tested was 50 µm/ mL, more than 100 µM. 38 However, a more recent study has reported that concentrations as low as 25 µM can exert antiproliferative/proapoptotic effects on HUVECs. 39 These effects were associated with G1 arrest, upregulation of p53 and the cdk inhibitors p21 and p27, downregulation of survivin, and suppression of NF-κB and Akt activation. As in the case of DIM, the proximal molecular target responsible for these effects of silibinin remains unclear, although the inhibition of NF-κB activation could likely account for some of silibinin's effects. Other effects of silibinin on HUVECs include a suppression of matrigel migration and invasion, decrease of matrix metalloproteinase-2 (MMP-2) secretion, and inhibition of capillary tube formation. These effects of silibinin were dose dependent and were significant at concentrations as low as 25 µM. Other investigators have confirmed that silibinin, in clinically achievable concentrations, can promote apoptosis in endothelial cells-this time using the ECV304 human endothelial cell line. 32 A third group has recently reported that in low micromolar concentrations, silibinin upregulates expression of VEGFR-1 (also known as Flt-1) in the EA.hy 926 endothelial cell line; expression of VEGFR-2 (KDR) is not influenced. 36 Since Flt-1 appears to act as a decoy receptor, 40 impeding access of the crucially important KDR receptor to its agonist VEGF, this mechanism may diminish the efficacy of VEGF signaling. (And it may be nicely complementary to the reported ability to eicosapentaenoic acid to downregulate KDR expression by endothelial cells in vitro. 41 
)
Marked tumor-retardant effects are observed in nude mice fed silibinin as 0.1% of diet. Extrapolating to humans (assuming a weight of 70 kg and normalizing silibinin dose to the three fourths power of relative body weights), this might correspond to an intake of about 1.5 g silibinin daily, or approximately 2.5 g daily of milk thistle extract, within the upper range of doses used to manage clinical hepatic disorders. It is encouraging to note that silibinin/silymarin is very safe in rodents-no LD50 can be established-and is noted for a low incidence of side effects (and no dangerous complications) in humans. 12 However, since silibinin is poorly water soluble, the bioavailability of silibinin preparations is variable 42, 43 ; this should be considered when designing nutraceuticals for use in cancer therapy. In light of silibinin's angiostatic potential, its demonstrable tumor-retardant activity in several xenograft models, its excellent clinical tolerance during decades of prior use, and its documented clinical utility in hepatic disorders (suggesting that physiologically meaningful concentrations can be achieved after oral administration), the inclusion of silibinin in MAT protocols appears warranted.
Defining Mechanisms: EGCG Versus VEGFR-2
The original essay on MAT could only speculate vaguely regarding the possible mechanism responsible for the documented angiostatic effect of oral green tea in rodents. However, recent evidence suggests that the endothelial KDR receptor (VEGFR-2) may be the chief target of EGCG in this regard.
In the main, the rather ample research literature pertaining to the effects of green tea polyphenols on endothelial cells in vitro is quite disappointing, inasmuch as most studies use concentrations of EGCG that would appear impossible to achieve by oral administration of tolerable doses. In light of the findings of recent phase I/phase II studies, there seems to be general agreement that feasible oral intakes of green tea polyphenols will not sustain serum concentrations of EGCG in excess of 1 µM. 15, 16 Yet very few studies have examined the impact of submicromolar concentrations of this agent. A very fortunate exception is a recent report by Beliveau and colleagues, who report that, even in submicromolar concentrations, EGCG can inhibit the increase in tyrosine phosphorylation of VEGFR-2 evoked by VEGF in bovine aortic endothelial cells. 44 At 1 µM, inhibition of this phosphorylation exceeded 75%, with nearly complete inhibition being noted at 10 µM. The inhibition achieved was comparable in potency to that seen with SU5416, said to be a "potent and selective" synthetic inhibitor of VEGFR-2 activity. This effect appeared to reflect inhibition of the kinase activity of the receptor, rather than an influence on phosphatase activity. Independent confirmation that EGCG can potently inhibit VEGFR-2 activity has been provided by Kay and colleagues, who demonstrated that EGCG suppresses the tyrosine phosphorylation of VEGFR-2 in chronic lymphocytic leukemia cells exposed to VEGF. 45 The lowest concentration of EGCG tested, approximately 6 µM, produced substantial inhibition in this regard, as judged from the photos of the immunoblots. Unfortunately, no quantitative data were published in this regard, and an IC50 was not calculated, but the findings appear consistent with those of Beliveau in endothelial cells.
Inasmuch as VEGFR-2 is the chief mediator of VEGF's influence on endothelial cell proliferation and migration, the impact of EGCG on VEGFR-2 activation may provide a satisfying explanation for the inhibition of VEGF-evoked corneal neovascularization in rabbits achieved by oral green tea in the classic report of Cao and Cao. 46 Moreover, since VEGF is usually a key mediator of tumor-evoked angiogenesis, this mechanism might also explain tumor-retardant effects of oral green tea reported in rodent models. [47] [48] [49] The ability of EGCG to inhibit matrix metalloproteinases has been proposed as a key mediator of its cancer-retardant activity. 50 Indeed, Beliveau and colleagues have reported that EGCG inhibits MMP-9, with an IC50 of only 0.3 µM. 51 However, the inhibition of MMP-2, another collagenase activity used by migrating endothelial cells, was much less potent, with an IC50 of 6 µM. Unless both of these activities were substantially inhibited, it seems unlikely that such inhibition could have a rate-limiting impact on the angiogenic process. It can be concluded that protease inhibition probably does not contribute importantly to the angiostatic activity of oral green tea polyphenols.
To date, clinical evaluation of high-dose oral green tea or green tea extracts has not shown a clear impact on the clinical course of cancer. [52] [53] [54] However, given the fact that these initial studies did not include placebotreated control groups, they are not designed to confirm or quantify a tumor-retardant effect less dramatic than tumor stasis or outright regression. Nonetheless, the absence of objective responses in a recent phase II study in prostate cancer led the authors to conclude that "green tea, as administered in this trial, does not merit further investigation in the treatment of patients with androgen independent prostate carcinoma." 53 To justify their trial, the authors cited studies employing oral green tea polyphenols in tumorbearing rodents; none of these studies report a regression of established tumors following green tea administration, yet the authors evidently hoped or expected to see such regressions in their clinical study. In any case, it would clearly be unrealistic to expect a partial inhibition of VEGFR-2 to have a dramatic impact on tumor spread. The more realistic hope is that in conjunction with other measures that attack the angiogenic process from other angles, green tea polyphenols can make a worthwhile if unspectacular contribution to an overall regimen that achieves meaningful increases in survival time and that, used in conjunction with cytotoxic therapies, may sometimes increase chances for a cure.
Tetrathiomolybdate Versus NF-κB
Recent studies by Merajver and colleagues offer interesting insight into mechanisms responsible for the angiostatic efficacy of copper depletion, as mediated by TM. Working with the SUM149 cell line, derived from a human inflammatory breast carcinoma, these researchers demonstrated that TM treatment of these cells decreased their secretion of the angiogenic factors VEGF, FGF2, IL-1, IL-6, and IL-8; this effect appeared to be physiologically significant since conditioned media obtained from TM-treated cells were much less effective in evoking angiogenesis in the rat aortic ring assay. 55 Since NF-κB plays a direct role in the transcriptional induction of most of these angiogenic factors, the authors then assessed the impact of TM treatment on the NF-κB activity of SUM149 cells. Using a vector containing 4 κB consensus sequences upstream of the luciferase reporter gene, as well as nuclear supershift analysis, they were able to demonstrate that TM does indeed inhibit NF-κB activity in these cells, an effect that was blocked by coadministering copper; the decrease in luciferase activity attributable to TM treatment was 62%.
To assess the role of NF-κB downregulation in the tumor-retardant effect of TM in vivo, the researchers transfected SUM149 cells with a dominant-negative IκBα expression vector, which suppressed NF-κB activity. 56 Tumors derived from these cells grew much more slowly than those stemming from native SUM149 cells; indeed, their rate of growth was quite comparable to that seen when SUM149 tumors were grown in TMtreated mice. Moreover, they observed that TM treatment had no discernible impact on the growth rate of the tumors derived from the dn-IκBα-transfected cell line; these findings are all consistent with the possibility that NF-κB downregulation in the tumor-leading to a global suppression of angiogenic factor secretion-is the chief mechanism whereby TM-mediated copper depletion retards angiogenesis and tumor growth.
These findings suggest a number of questions: Can copper depletion downregulate NF-κB activity in most or all tumors? What is the mechanism by which copper depletion achieves this downregulation? (The signaling intermediates known to play a role in NF-κB activation are not known to be directly copper dependent.) Will TM complement the activity of other agents, such as salicylates, which can inhibit NF-κB activation? Do mechanisms independent of NF-κB contribute to the impact of TM on some angiogenic cytokines? (In this regard, a recent report that copper suppresses proteasomal degradation of HIF-1α-another major transcriptional regulator of angiogenic factors-is intriguing. 57 ) Will TM prove useless in the treatment of tumors in which NF-κB overactivity plays little role in the expression of proangiogenic factors? Does TM treatment have minimal direct impact on the function of endothelial cells? Or can it influence endothelial function by suppressing NF-κB activity in these cells as well (in light of NF-κB's role in angiogenesis, as discussed below)? The notion that TM's angiostatic activity may be directed solely against tumor cells is somewhat difficult to square with Gullino's pioneering observation that copper deficiency in rabbits inhibited corneal neovascularization evoked by topical PGE1. 58 In any case, the clinical assessment of TM's utility as a cancer therapy is well under way. In a recent review, Brewer notes that 8 phase II studies addressing specific cancers are currently assessing TM therapy. 59 The results of a phase I/II study involving numerous types of advanced metastatic cancer were encouraging: freedom from progression averaged 11 months. TM evidently has intriguing promise as an angiostatic strategy, and we should soon have a better understanding of its clinical potential in this regard.
Glycine Versus NADPH Oxidase
Amin and colleagues 60 have provided independent confirmation of Thurman et al's initial report that high-dose dietary glycine can exert an angiostatic effect. 61 They demonstrated that 100 µM glycine inhibits angiogenesis in the chorioallantoic membrane assay by more than 50%. In glycine-fed rats subjected to a novel wound-healing assay (fibrin Z-chamber), formation of granulation tissue was decreased by 30%, and microvessel density was 15% lower. In rats implanted with R3230 mammary adenocarcinoma, dietary glycine decreased tumor growth by 15%, and microvessel density was 20% lower. These effects, though less dramatic than those reported by Thurman et al with B16 melanoma in mice (65% inhibition of tumor growth), nonetheless achieved statistical significance.
What can account for the angiostatic activity of glycine? Thurman et al believed that this activity directly targeted endothelial cells, inasmuch as, in vitro, glycine suppressed the proliferation of endothelial cells but not that of tumor cells (whose growth nonetheless was inhibited in vivo). 61 This group demonstrated that endothelial cells express glycine-gated chloride channels, similar to neuroinhibitory chloride channels found in the central nervous system; glycine opens these channels, hyperpolarizing the plasma membrane. 62 Strychnine, which inhibits activation of these channels, abolished the impact of glycine on endothelial cell proliferation; thus, these channels appear to mediate the impact of glycine on endothelial function. But how could plasma membrane polarity influence endothelial function?
A clue may be provided by recent evidence that constitutive or stimulated activity of a plasma membrane NADPH oxidase is essential for optimal activity of VEGF, bFGF, and serum in cultured endothelial cells; selective inhibitors of this oxidase impair the proliferative and migratory responses of endothelial cells to these angiogenic growth factors. [63] [64] [65] A likely explanation is that the hydrogen peroxide generated by NADPH oxidase activity inhibits protein tyrosine phosphatases, 66 which target phosphorylated tyrosine residues in the receptors for these agonists; NADPH oxidase activity would thus upregulate signaling through these tyrosine kinase receptors. 64 But plasma membrane potential has an important regulatory influence on NADPH oxidase activity: depolarization boosts its activity, apparently by promoting membrane translocation of Rac, whereas membrane hyperpolarization has an inhibitory effect. [67] [68] [69] [70] [71] Thus, it is reasonable to propose that glycine, through its hyperpolarizing action, suppresses NADPH oxidase activity, thereby upregulating tyrosine phosphatases that oppose the angiogenic activity of VEGF, bFGF, and serum. 72 An easy way to test this hypothesis would be to show that inhibition of NADPH oxidase abolishes the impact of glycine on endothelial cell function. A corollary of these considerations is that pharmaceutical inhibitors of NADPH oxidase, if and when such become clinically available, may have useful angiostatic activity. 73 
Selenium and Thioredoxin Reductase
The suggestion that supplemental selenium could be a useful component of MAT stemmed from the report from Jiang and colleagues that increased but nontoxic dietary intakes of selenium reduced microvessel density and VEGF content in carcinogen-induced rat mammary carcinomas. 74 How might selenium status influence VEGF production? A clue is provided by a recent study examining the influence of selenium on VEGF production by cultured endothelial cells. 75 Growing these cells in selenium-deficient medium was associated with increased production of VEGF, increased expression of VEGFR-2, and an increase in the proliferation and migration of these cells. In cells with good selenium status, treatment with an inhibitor of thioredoxin reductase replicated the effects of selenium deficiency on endothelial behavior, whereas inhibition of glutathione peroxidase had no influence in this regard; thus, good thioredoxin activity in endothelial cells appears to restrain autocrine production of VEGF as well as VEGFR-2 expression, likely because it influences the oxidation status of cysteine residues in signaling proteins. It is interesting to note that thioredoxin reductase activity tends to be more responsive to selenium status than glutathione peroxidase activity; the latter is maximized by moderate selenium intakes likely provided by most U.S. diets, whereas it may be more feasible to modulate thioredoxin reductase activity with supplemental selenium. 76 How thioredoxin reductase activity modulates VEGF and VEGFR-2 expression in endothelial cells remains unexplained. Theoretically, thioredoxin reductase activity could downregulate NF-κB activation by counteracting oxidant effects, 77 although, perplexingly, reducing activity can boost the transcriptional activity of nuclear NF-κB, and there is a report that thioredoxin reductase-1 overexpression upregulates NF-κB activity in endothelial cells. 78 Another pertinent question is whether glutathione peroxidase or thioredoxin reductase activity influences the activities of the oxidizable tyrosine phosphatases that modulate the activity of tyrosine kinase receptors for VEGF and other angiogenic growth factors.
Modulation of thioredoxin reductase activity can be achieved with moderate intakes of selenium that are clearly nontoxic. 76 Higher intakes of selenium, by evoking mechanisms independent of seleniumdependent enzymes, may also exert angiostatic effects reflecting decreased proliferation and increased apoptosis in endothelial cells. These mechanisms may be mediated by methylselenide and metabolites thereof. 79, 80 However, these effects are dubiously relevant to dietary intakes of selenium in the nutritional range (ie, less than 1000 µg daily). Although Lu and Jiang noted that methylselenide can inhibit endothelial cell proliferation in vitro in concentrations comparable to that of plasma selenium in healthy subjects, 79 they failed to note that most plasma selenium occurs as seleno-amino acids in intact proteins, which are essentially physiologically inert until their selenium in liberated during catabolism; thus, the pool of "free" selenium in plasma is just a very small fraction of the total plasma content. Nonetheless, the possibility that supranutritional but still tolerable intakes of selenium could suppress tumor angiogenesis by mechanisms independent of selenium-dependent enzymes deserves further evaluation. Corcoran and colleagues have recently reported that at a 3 ppm concentration in drinking water, sodium selenite slowed the growth and suppressed the metatstatic spread of PC3 prostate tumors in nude mice, an effect associated with decreased tumor microvessel density. 81 Although one might expect this level of intake to be borderline toxic, it did not influence weight gain in the mice nor induce dermatological changes characteristic of selenium toxicity. These results should encourage clinical exploration of the impact of supplemental selenium intakes in doses up to 2000 µg daily, which potentially could induce nausea and hair loss in some subjects. 82 
Vegan Diets and Fish Oil
The previous discussion of MAT recommended a verylow-fat whole-food vegan diet, coupled with aerobic exercise training, based on the presumption that such a regimen would downregulate systemic IGF-I activity and thereby influence the angiogenic process. 1 Indeed, in cancers that are IGF-I responsive, this hormone can promote increased production of VEGF and other angiogenic factors. [83] [84] [85] [86] [87] [88] Moreover, there is evidence IGF-I may also act directly on endothelial cells to upregulate their response to VEGF; pretreatment of endothelial cells with an antagonist of the type 1 IGF receptor suppresses the response of MAP kinases to VEGF stimulation, and systemic administration of this antagonist inhibits the neovascularization evoked by retinal hypoxia. 89 Little new evidence has emerged recently pertaining to the impact of systemic IGF-I activity, or of low-fat vegan diets, on the angiogenic process. Nonetheless, recent reports provide confirmation that such diets may have potential for slowing the growth and spread of certain cancers. Thus, Barnard and colleagues have shown that serum derived from patients who have been practicing a very-low-fat quasi-vegan diet for several weeks and exercising regularly has lower effective IGF-I activity. Moreover, when androgen-sensitive human prostate cancer cells (LNCaP), or a human mammary cancer cell line, are incubated in such serum, their proliferation rates are lower and their apoptotic rates higher than when these cells are incubated in serum from the same subjects obtained prior to their diet and exercise regimen; on the other hand, the PC3 androgen-insensitive prostate cancer cell line was not responsive in this regard. [90] [91] [92] [93] Even more clinically pertinent is a recent report from Ornish, providing a 1-year follow-up on patients with early prostate cancer in the "watchful waiting" phase, who were randomized to either a very-low-fat, strictly vegan diet complemented by exercise training and stress control techniques or a control regimen. 94 After a year, average prostate-specific antigen values had dropped by 4% in the treatment group, whereas they had risen by 6% in the control group; furthermore, 6 patients in the control group had elected to initiate conventional treatment of their cancer, whereas none of the treated group chose to do so. These results may be viewed as confirmation of the principle that feasible lifestyle regimens can downregulate systemic IGF-I activity 93, 95, 96 and that such downregulation may slow the spread of certain types of cancer, in part by influencing angiogenesis.
Despite the fact that fish-oil-rich diets slow the spread of many types of cancer in rodents, [97] [98] [99] [100] [101] [102] and despite evidence that suppression of angiogenesis may be at least partially responsible for this effect, 99, [101] [102] [103] there appear to have been few recent attempts to clarify the impact of long-chain omega-3s on the angiogenic process. The most pertinent finding in this regard remains the original report by Murota and colleagues that, in vitro, incubation of bovine carotid artery endothelial cells with eicosapentaenoic acid (EPA) decreases their expression of VEGFR-2, an effect associated with a decrease in VEGF-evoked proliferation; no effect on response to bFGF was seen. 103, 104 More recently, this group has demonstrated that this effect can be more potently evoked by docosapentaenoic acid, a metabolite of EPA produced by an elongation reaction and richly supplied by seal oil. 105 To date, most interest in fish oil supplementation in clinical cancer has centered on the potential of longchain omega-3s to counteract cachexia in patients with advanced cancer. Fish oil intakes providing 2 to 4 g EPA daily appear to have some modest utility in this regard. [106] [107] [108] It should be borne in mind that high intakes of fish oil omega-3s, over a long period of time and in the context of a low dietary fat intake, may be required to achieve a physiologically meaningful modulation of the EPA/arachidonate balance in tissues.
Dual-Purpose Targets
Cytotoxic therapies that provoke apoptosis by directly or indirectly damaging DNA remain a mainstay of cancer therapy. However, a novel approach that might be called signal modulation therapy (SMT) attempts to influence the behavior of cancers by suppressing the activity of signaling intermediates whose upregulation is responsible for the increased rate of proliferation, decreased susceptibility to apoptosis, and propensity to invade tissues and provoke angiogenesis that characterize advanced cancer. Imatinib (Gleevec), a specific inhibitor of the constitutively active Bcr-Abl tyrosine kinase expressed by chronic myelogenous leukemia cells, is one of the first signal-modulating agents approved for clinical use. 109 Therapies that decrease or increase specific hormonal activities may also be viewed as signal-modulating agents. A number of other potential targets for SMT are under active investigation; these targets include various tyrosine kinase receptors (EGFR, HER2, type 1 IGF receptor, c-Kit), the nonreceptor tyrosine kinase c-Src, mTOR, cox-2, NF-κB, Stat3, HIF-1α, hsp90, farnesyl transferase, and PKA type 1, among others. 110 Agents that inhibit EGFR and HER2 have already received approval, and many other signal-modulating drugs are in various phases of clinical development. While therapies addressing any single target seem unlikely to achieve substantial or lasting efficacy, it is reasonable to hope that combination therapies addressing several targets in a functionally complementary way will have greater potential, hence "multifocal SMT." [110] [111] [112] SMT might also be employed in conjunction with cytotoxic therapies, the intent being to downregulate mechanisms that protect cancer cells from cytotoxinmediated apoptosis or that expel drugs from cancer cells. 113, 114 Several signaling intermediates that are potential targets for SMT also play a role in the angiogenic process; thus, SMTs that address these targets could simultaneously achieve an angiostatic effect. Such targets may include cox-2, NF-κB, Stat3, hsp90, and c-Src.
In endothelial cells, VEGF, FGF2, platelet-activating factor, and the ligation of integrins αvβ3 and α5β1 can all activate NF-κB. [115] [116] [117] [118] [119] Activation of NF-κB protects endothelial cells from apoptosis during the angiogenic process and also appears to play an important role in capillary tube formation. [117] [118] [119] [120] [121] [122] [123] [124] [125] The homeobox transcription factor Gax, which downregulates endothelial activation and angiogenesis, is notable for suppressing NF-κB's transcriptional activity. 126 The most specific way to inhibit NF-κB activation is to suppress the activity of IκB kinase-β; although many specific inhibitors of this kinase are in development, aspirin, salicylic acid, and sulindac, more generally known for their cox-inhibitory activity, are also effective inhibitors of IκB kinase-α, in high clinical doses. 127, 128 Indeed, a recent study shows that high-dose aspirin or salicylate markedly inhibits Matrigel-FGF2-evoked angiogenesis in rats. 129 Of course, the impact of salicylates on angiogenesis may also reflect their inhibitory activity for both isoforms of cyclooxygenase. Indeed, there is evidence that cox-2, whose endothelial expression is evoked during angiogenesis (in part owing to NF-κB activation), also plays a role in the angiogenic process. 130 This is most elegantly demonstrated by studies showing that the growth of human tumors is markedly suppressed in cox-2 knockout mice (ie, mice that lack cox-2 activity); not surprisingly, the microvascular density of tumors in these mice is subnormal. 1 3 1 Cyclooxygenase activity appears to be of especial importance for migration and capillary tube formation; conceivably, cox-2 mediates some of NF-κB's activity in this regard. [132] [133] [134] Recent evidence indicates that PGE2-mediated upregulation of the CXCR4 chemokine receptor may be largely responsible for the influence of cyclooxygenase activity on capillary tube formation. 135 The angiostatic potential of salicylate therapy may thus reflect joint inhibition of NF-κB and cyclooxygenase activity; such therapy can be relatively safe if accompanied by misoprostol to prevent gastrointestinal ulceration. 136 Now that cox-2specific inhibitors have fallen under a cloud owing to their impact on thrombotic risk, researchers should take a closer look at the potential of salicylates in cancer therapy.
Overactivation of the nonreceptor tyrosine kinase c-Src plays a role in mitogenic signaling, apoptosis avoidance, and invasive behavior in many cancers; thus, specific inhibitors of this kinase are being evaluated as cancer drugs. [137] [138] [139] [140] (The fact that its constitutively active viral homolog v-Src has transforming activity does indeed suggest a role for upregulated c-Src activity in neoplastic behavior. 141 ) In endothelial cells, VEGF activates c-Src; this effect appears to be crucial for efficient endothelial migration. [142] [143] [144] Herbimycin A, a relatively selective inhibitor of c-Src, inhibits VEGFinduced endothelial proliferation and capillary tube formation, and injection of this drug in rats substantially inhibits hyperoxia-induced preretinal neovascularization. 145 Endothelial cells transfected with kinase-dead c-Src fail to spread and form normal capillary tubes in vitro. 146 No selective c-Src inhibitors are currently in clinical trials, but several such agents are in preclinical development and appear to have potential for treatment of both cancer and osteoporosis. 147 Constitutive activation of Stat3 is commonly encountered in advanced cancers; c-Src often plays a role in this activation. [148] [149] [150] [151] Stat3 resembles NF-κB in the sense that its overactivity promotes proliferation while also exerting antiapoptotic effects that render cancer cells chemoresistant. Small molecule inhibitors of Stat3's transcriptional activity are currently under development in preclinical studies. [152] [153] [154] In endothelial cells, VEGF promotes the activating phosphorylation and nuclear translocation of Stat3. 155 Moreover, when endothelial cells are transfected with dominant-negative Stat3, migration and capillary tube formation are markedly suppressed. 155 Thus, when and if Stat3 inhibitory drugs become available, they can be expected to have direct effects on both cancer and endothelial cells that will slow cancer proliferation, render cancer more susceptible to cytotoxic agents, and impede angiogenesis.
In many cancers, upregulated activity of the "cellular chaperone" hsp90 prolongs the half-lives of many proproliferative, antiapoptotic signaling intermediates by protecting them from proteasomal degradation. 156, 157 Drugs that bind to hsp90 in such a way as to inhibit its chaperone activity are currently in clinical trials, namely, the geldanamycin analogs 17-AAG and the orally available 17-DMAG. [158] [159] [160] [161] For reasons that remain somewhat obscure, hsp90 in cancer cells tends to be preferentially sensitive to these agents. 162 One recent study highlights the angiostatic potential of 17-DMAG. In mice, oral 17-DMAG dose dependently inhibits Matrigel/FGF2-evoked angiogenesis. 163 In cultured endothelial cells, this drug suppresses the proliferative response to VEGF or FGF2, boosts apoptosis, and inhibits migration, invasion, and capillary tube formation. Similar results were seen with 17-AAG. Whether these drugs can achieve an angiostatic effect in concentrations that are achievable with clinically tolerable doses remains to be seen.
Overview
Pharmaceutical companies worldwide are working diligently to develop a wide range of drugs and antibodies intended to suppress angiogenesis. 164, 165 Many of these specifically target VEGF signaling. Monoclonals directed at integrins or cadherins expressed by endothelial cells during the angiogenic process have shown promise in preclinical studies. The antiangiogenic natural peptides angiostatin and endostatin are still in the pipeline. Other agents such as combrestatins, thalidomide, and 2-methoxyestradiol demonstrate angiostatic activity in rodents, although their mechanisms of action remain unclear. It is greatly to be hoped that at least a few of these agents will demonstrate sufficient efficacy in tolerable doses to enter clinical practice. However, with the exception of TM, the agents that have been recommended here-diindolylmethane, silibinin, green tea extract, fish oil, glycine, and selenium, to be complemented by a low-fat vegan diet and exercise training-are nutraceuticals that are readily available (at least in the United States) and that are known to be well tolerated, at least within traditional dose ranges. (With respect to TM, it also is already available for clinical use, it is orally administrable, and it is well tolerated when used with appropriate care. 166 ) It should be feasible to combine a number of these agents in nutraceutical products designed to suppress angiogenesis, an option that is far less practical with drugs. Moreover, effective doses of these nutraceuticals will be considerably less expensive than new angiostatic drugs that achieve approval, at least until these drugs are off patent. Good tolerance and affordability are important considerations when one considers that, unless a tumor can be totally eradicated, angiostatic therapy regimens will need to be administered virtually without cessation for the rest of a cancer patient's life.
Since the recommended agents address a range of targets-some suppress the production of angiogenic hormones by the tumor, whereas others have a direct impact on endothelial cells-it is reasonable to hope that at least complementary angiostatic activity will be achieved when these agents are administered in combination. A number of these agents target VEGF signaling: TM, selenium, and a vegan diet may suppress tumor secretion of this factor, ECGC inhibits the autophosphorylation of VEGFR-2, glycine may boost the activity of tyrosine phosphatase activity targeting this receptor, EPA decreases VEGFR-2 expression (at least in vitro), whereas silibinin upregulates expression of the "decoy" receptor VEGFR-1. Yet these agents have additional activities: TM inhibits tumor production of a range of angiogenic factors, glycine may influence signaling via several endothelial tyrosine kinase receptors, and DIM and silibinin act directly on endothelial cells to suppress proliferation, migration, and capillary tube formation through mechanisms that remain unclear. Clearly, it is desirable to assess the impacts of combinations of these agents in rodent xenograft models. If such studies yield promising results, the development of nutraceutical products combining these agents in a convenient format can go forward. Assuming that such products prove effective, they might make excellent adjuvants for new angiostatic drugs as these eventually become available.
With respect to dual-purpose agents, many of these are not yet clinically available, but aspirin and salicylic acid clearly are, and high-dose salicylate therapy for cancer-accompanied by misoprostol or other appropriate measures to prevent gastrointestinal ulceration-merits much further evaluation, both in animal models and in the clinic. Joint inhibition of NF-κB and cyclooxygenase can be expected to diminish the aggressive behavior of many advanced cancers, improve their chemosensitivity, suppress their secretion of various angiogenic factors, and act directly on endothelial cells to impede the angiogenic process. The impact of salicylates on NF-κB activity is likely to prove complementary to that of TM. The paucity of research on salicylates as anticancer drugs serves as an example of how the pursuit of profit all too often dominates the medical research agenda.
